Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2022 | 160 | 4.670 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 141 | 4.140 |
Why?
|
| Parotid Neoplasms | 3 | 2021 | 14 | 2.190 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 20 | 2.070 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 18 | 2.050 |
Why?
|
| Laryngeal Neoplasms | 5 | 2023 | 33 | 1.980 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 25 | 1.810 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 123 | 1.340 |
Why?
|
| Neck Dissection | 3 | 2021 | 20 | 1.270 |
Why?
|
| Retrospective Studies | 23 | 2023 | 3297 | 1.170 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 185 | 1.140 |
Why?
|
| Facial Nerve | 3 | 2021 | 13 | 1.090 |
Why?
|
| Parotid Gland | 3 | 2021 | 16 | 1.090 |
Why?
|
| Dissection | 3 | 2021 | 22 | 1.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 80 | 1.040 |
Why?
|
| Salvage Therapy | 3 | 2023 | 36 | 0.980 |
Why?
|
| Postoperative Complications | 5 | 2020 | 860 | 0.930 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 19 | 0.920 |
Why?
|
| Drug Utilization | 2 | 2020 | 22 | 0.870 |
Why?
|
| Humans | 38 | 2023 | 26025 | 0.860 |
Why?
|
| Narcotics | 2 | 2020 | 37 | 0.840 |
Why?
|
| Analgesia | 2 | 2020 | 35 | 0.840 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.810 |
Why?
|
| Survival Rate | 8 | 2021 | 321 | 0.780 |
Why?
|
| Male | 25 | 2023 | 14008 | 0.760 |
Why?
|
| Middle Aged | 20 | 2021 | 8507 | 0.740 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.740 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 9 | 0.730 |
Why?
|
| Surgical Instruments | 1 | 2021 | 21 | 0.730 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.730 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.730 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 29 | 0.720 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 21 | 0.720 |
Why?
|
| Glottis | 1 | 2020 | 4 | 0.720 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 45 | 0.710 |
Why?
|
| Prescriptions | 1 | 2020 | 17 | 0.710 |
Why?
|
| Aged | 19 | 2023 | 8704 | 0.700 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 61 | 0.680 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 302 | 0.680 |
Why?
|
| Female | 22 | 2021 | 14397 | 0.670 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.660 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2019 | 3 | 0.660 |
Why?
|
| Pharyngectomy | 1 | 2019 | 3 | 0.650 |
Why?
|
| Recovery of Function | 1 | 2020 | 279 | 0.650 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 56 | 0.640 |
Why?
|
| Sarcoma | 1 | 2021 | 142 | 0.610 |
Why?
|
| Databases, Factual | 4 | 2021 | 325 | 0.510 |
Why?
|
| Adult | 13 | 2020 | 7363 | 0.470 |
Why?
|
| Tonsillar Neoplasms | 1 | 2014 | 3 | 0.460 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 14 | 0.460 |
Why?
|
| Dura Mater | 1 | 2014 | 16 | 0.450 |
Why?
|
| Laryngectomy | 4 | 2023 | 21 | 0.450 |
Why?
|
| Teratoma | 1 | 2012 | 4 | 0.420 |
Why?
|
| Surgical Flaps | 1 | 2012 | 50 | 0.400 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.390 |
Why?
|
| Angioedema | 1 | 2011 | 2 | 0.390 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 313 | 0.390 |
Why?
|
| Airway Obstruction | 1 | 2011 | 17 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 24 | 0.390 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.380 |
Why?
|
| Ear Diseases | 1 | 2011 | 3 | 0.380 |
Why?
|
| Nose Diseases | 1 | 2011 | 7 | 0.380 |
Why?
|
| Gravitation | 1 | 2010 | 1 | 0.370 |
Why?
|
| Barotrauma | 1 | 2010 | 3 | 0.370 |
Why?
|
| Accidents | 1 | 2010 | 2 | 0.370 |
Why?
|
| Hypersensitivity | 1 | 2011 | 39 | 0.370 |
Why?
|
| Head Movements | 1 | 2010 | 4 | 0.370 |
Why?
|
| Tympanic Membrane | 1 | 2010 | 4 | 0.370 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 40 | 0.370 |
Why?
|
| Ear Canal | 1 | 2010 | 4 | 0.370 |
Why?
|
| Leisure Activities | 1 | 2010 | 13 | 0.370 |
Why?
|
| Tongue | 2 | 2021 | 9 | 0.360 |
Why?
|
| Acceleration | 1 | 2010 | 19 | 0.360 |
Why?
|
| Edema | 1 | 2010 | 24 | 0.360 |
Why?
|
| Prognosis | 3 | 2019 | 750 | 0.350 |
Why?
|
| Chylothorax | 1 | 2010 | 1 | 0.350 |
Why?
|
| United States | 6 | 2021 | 1981 | 0.340 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 326 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 77 | 0.330 |
Why?
|
| Papillomaviridae | 2 | 2022 | 18 | 0.330 |
Why?
|
| Young Adult | 6 | 2020 | 1853 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2020 | 1823 | 0.330 |
Why?
|
| Betacoronavirus | 2 | 2020 | 70 | 0.320 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 158 | 0.310 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 82 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 85 | 0.310 |
Why?
|
| Lens Cortex, Crystalline | 1 | 2007 | 3 | 0.300 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2007 | 6 | 0.300 |
Why?
|
| Lens, Crystalline | 1 | 2007 | 33 | 0.290 |
Why?
|
| Adolescent | 4 | 2020 | 2064 | 0.280 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3292 | 0.280 |
Why?
|
| Risk Assessment | 2 | 2019 | 622 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 21 | 0.270 |
Why?
|
| Margins of Excision | 2 | 2021 | 27 | 0.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 27 | 0.220 |
Why?
|
| Neck | 2 | 2023 | 26 | 0.220 |
Why?
|
| Otolaryngology | 2 | 2020 | 29 | 0.220 |
Why?
|
| Pilot Projects | 2 | 2022 | 378 | 0.210 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 13 | 0.210 |
Why?
|
| SEER Program | 2 | 2019 | 38 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4659 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.200 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 277 | 0.200 |
Why?
|
| Age Factors | 3 | 2019 | 744 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2021 | 1659 | 0.200 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 62 | 0.190 |
Why?
|
| Length of Stay | 2 | 2023 | 301 | 0.190 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 32 | 0.190 |
Why?
|
| Cytological Techniques | 1 | 2021 | 12 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2020 | 449 | 0.180 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.180 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.180 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.180 |
Why?
|
| Risk Factors | 3 | 2021 | 2243 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 28 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.170 |
Why?
|
| Paraganglioma | 1 | 2019 | 3 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 16 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2020 | 121 | 0.170 |
Why?
|
| Frailty | 1 | 2019 | 35 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.170 |
Why?
|
| Head | 1 | 2019 | 22 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2019 | 62 | 0.160 |
Why?
|
| Medical Illustration | 1 | 2019 | 14 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 161 | 0.160 |
Why?
|
| Larynx | 1 | 2019 | 10 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 108 | 0.160 |
Why?
|
| Pharynx | 1 | 2019 | 12 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 35 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 29 | 0.160 |
Why?
|
| Morphine | 1 | 2019 | 61 | 0.160 |
Why?
|
| Reference Values | 1 | 2019 | 184 | 0.160 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1712 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 295 | 0.160 |
Why?
|
| Telemedicine | 1 | 2020 | 98 | 0.150 |
Why?
|
| Aging | 1 | 2007 | 1535 | 0.150 |
Why?
|
| Carcinoma | 1 | 2018 | 59 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 485 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mucormycosis | 1 | 2017 | 9 | 0.140 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 202 | 0.140 |
Why?
|
| Markov Chains | 1 | 2015 | 30 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 20 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 42 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 124 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 93 | 0.120 |
Why?
|
| Rhinitis | 1 | 2017 | 139 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 156 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 93 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 51 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 335 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 342 | 0.110 |
Why?
|
| Drainage | 2 | 2010 | 46 | 0.100 |
Why?
|
| Cricoid Cartilage | 1 | 2012 | 1 | 0.100 |
Why?
|
| Forearm | 1 | 2012 | 19 | 0.100 |
Why?
|
| Mouth Floor | 1 | 2011 | 1 | 0.100 |
Why?
|
| Tongue Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2012 | 30 | 0.100 |
Why?
|
| Trachea | 1 | 2012 | 45 | 0.100 |
Why?
|
| Laryngoscopy | 1 | 2011 | 18 | 0.100 |
Why?
|
| Patient Admission | 1 | 2011 | 25 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 67 | 0.090 |
Why?
|
| Otoscopy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 8 | 0.090 |
Why?
|
| Hearing Tests | 1 | 2010 | 8 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 93 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hematoma | 1 | 2010 | 15 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 279 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 358 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 228 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 306 | 0.080 |
Why?
|
| Pandemics | 2 | 2020 | 239 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 22 | 0.070 |
Why?
|
| Lasers | 1 | 2007 | 17 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 73 | 0.070 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Hypertension | 1 | 2010 | 217 | 0.070 |
Why?
|
| Fetus | 1 | 2007 | 32 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 180 | 0.070 |
Why?
|
| Immobilization | 1 | 2023 | 14 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 713 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 55 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 27 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 193 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2021 | 235 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 18 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Animals | 1 | 2007 | 3389 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 53 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 33 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 62 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 290 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 166 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 442 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 844 | 0.040 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.040 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.040 |
Why?
|
| Nasal Surgical Procedures | 1 | 2017 | 10 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.030 |
Why?
|
| Nose | 1 | 2017 | 36 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 189 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 174 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 222 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 148 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 171 | 0.030 |
Why?
|